What are the side effects of capmatinib?

Capmatinib (Capmatinib) is a targeted drug used to treat adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have mutations that cause mesenchymal epithelial transition (MET) exon 14. However, using capmatinib may cause some side effects.

In clinical studies of capmatinib, the most common adverse reactions were edema, nausea, musculoskeletal pain, fatigue, vomiting, dyspnea, cough and decreased appetite. The incidence rate of these adverse reactions reached ≥20%. In addition, there are serious adverse reactions that warrant attention, including dyspnea, pneumonia, pleural effusion, musculoskeletal pain, worsening of general health, interstitial lung disease (ILD)/pneumonitis, edema, and vomiting.

In addition to the adverse reactions listed above, clinical studies of capmatinib have identified other warnings and precautions. For example, use of capmatinib may cause interstitial lung disease (ILD)/pneumonitis, hepatotoxicity, pancreatic toxicity, allergic reactions, risk of photosensitivity, and toxicity to the embryo and fetus.

Therefore, when treating patients with capmatinib, doctors need to closely monitor patients for adverse reactions and take appropriate measures. If the patient develops serious adverse reactions such as dyspnea, pneumonia, pleural effusion, etc., he should stop taking the drug immediately and seek medical treatment. In addition, patients should be aware of the possible risk of allergic reactions and photosensitivity and avoid exposure to sunlight while taking capmatinib.

In conclusion, capmatinib is an effective targeted agent for the treatment of patients with metastatic non-small cell lung cancer. However, patients need to be aware of the side effects when using this drug and communicate closely with their doctor so that any adverse reactions can be detected and dealt with promptly.